Norvir (Ritonavir)

Ritonavir, the active ingredient in Norvir, is a protease inhibitor presented as an oral tablet for oral use. It treats HIV-1 infection and is used to boost the pharmacokinetic exposure of other protease inhibitors in adult patients.

GNH USA supplies Norvir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Norvir is a protease inhibitor used in the management of HIV‑1 infection and to enhance other antiretroviral agents.

- HIV‑1 infection: reduces viral load and improves immune function when used as part of combination therapy. - Pharmacokinetic boosting of other protease inhibitors: increases plasma concentrations of co‑administered protease inhibitors, allowing lower dosing. - Treatment‑experienced HIV‑1 patients: used in combination regimens to maintain viral suppression after prior therapy.

Ritonavir may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: occasional upset stomach. - Diarrhea: loose stools, often transient. - Abdominal pain: mild discomfort in the stomach area. - Headache: mild to moderate tension. - Fatigue: feeling unusually tired. - Dyslipidemia: elevated cholesterol or triglycerides.

Serious or Rare Side Effects: - Hepatotoxicity: liver enzyme elevations or hepatitis. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - QT prolongation: cardiac rhythm disturbances. - Pancreatitis: inflammation of the pancreas. - Severe hyperglycemia: marked increase in blood glucose. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction.

Before prescribing Ritonavir, clinicians should assess patient-specific risk factors and monitor relevant parameters.

- Liver function monitoring: check hepatic enzymes regularly. - Lipid profile assessment: evaluate cholesterol and triglycerides during therapy. - Cardiac evaluation: caution in patients with known QT‑prolonging conditions. - Drug interaction review: verify concomitant medications for CYP3A4 interactions. - Use in hepatic impairment: avoid or adjust dose in severe liver disease. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ritonavir interacts with many medicines due to potent CYP3A4 inhibition.

Major Interactions (Avoid): - Simvastatin or lovastatin: risk of severe myopathy. - Certain anti‑arrhythmics (e.g., amiodarone): may cause cardiac toxicity. - Pimozide: can lead to serious QT prolongation.

Moderate Interactions (Monitor Closely): - Other protease inhibitors: dose adjustments may be required. - Warfarin: monitor INR for altered anticoagulation. - Oral contraceptives: efficacy may be reduced, consider alternative contraception.